Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address unmet medical needs in the United States, Europe and internationally. It will report its Q4 2024 earnings on Feb.

Shares of Gilead Sciences Inc. GILD inched 0.59% higher to $93.95 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.10% to 6,

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the past five years and becoming the most valuable company in the world for a brief period (it's currently No.